immuno-oncology
AstraZeneca buys rights to Heptares experimental cancer treatment
August 6, 2015Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, HTL-1071, immuno-oncology
AstraZeneca has entered into a licensing agreement with Heptares for the global rights to the experimental cancer treatment HTL-1071. The …
Sanofi and Regeneron in immuno-oncology push
July 28, 2015Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1
Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …
Roche posts positive mid-stage trial results for atezolizumab
July 13, 2015Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine
A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
Lilly and AstraZeneca collaborate on cancer trials
May 29, 2015Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I
AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …
AstraZeneca signs immuno-oncology deal with UK firm
April 16, 2015Research and Development, Sales and Marketing AstraZeneca, IMCgp100, MEDI4736, MedImmune, Oxford, immuno-oncology, immunocore, melanoma, tremelimumab
UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies of potential new cancer treatments. …
Merck Serono in $826m immuno-oncology deal
March 31, 2015Research and Development, Sales and Marketing Intrexon, Merck, Merck Serono, T cell, biopharma, cart, immuno-oncology, t-cell
Merck Serono has announced a significant deal with Intrexon to develop and bring new cancer treatments to market. The German …
BMS in $1.5 billion immuno-oncology expansion
February 24, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology
Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
